| 词条 | Namilumab |
| 释义 |
| Verifiedfields = changed | verifiedrevid = 458284722 | type = mab | image = | alt = | mab_type = mab | source = u | target = CSF2 | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = {{cascite|changed|??}} | CAS_number = 1206681-39-1 | ATC_prefix = none | ATC_suffix = | UNII_Ref = {{fdacite|correct|FDA}} | UNII = MED485W763 | PubChem = | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = none | chemical_formula = | molecular_weight = }}Namilumab (alternative identifier MT203) is a human monoclonal antibody (class IgG1 kappa) that targets granulocyte macrophage-colon stimulating factor (GM-CSF)/colony stimulating factor 2 (CSF2) and is currently being researched for application in rheumatoid arthritis (RA) and psoriatic arthritis.[1][2][3] Clinical trials investigating the therapeutic utility of Namilumab have include phase I and phase II clinical trials to establish the safety, tolerability and preliminary therapeutic utility of the antibody in plaque psoriasis[4] and rheumatoid arthritis.[5][6] Namilumab was produced by Micromet Inc and is under development by Takeda Pharmaceuticals International.[3][7] References1. ^{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104 | journal = WHO Drug Information | volume = 24 | issue = 4 | year = 2010 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL104.pdf | format=PDF}} {{Monoclonals for immune system}}{{Cytokine receptor modulators}}{{monoclonal-antibody-stub}}{{antineoplastic-drug-stub}}2. ^{{Cite web|url=http://acrabstracts.org/abstract/namilumab-an-anti-granulocyte-macrophage-colony-stimulating-factor-gm-csf-monoclonal-antibody-results-of-the-first-study-in-patients-with-mild-to-moderate-rheumatoid-arthritis-ra/|title=Meeting Abstract: Namilumab, an Anti-Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Monoclonal Antibody: Results of the First Study in Patients with Mild-to-Moderate Rheumatoid Arthritis (RA)|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}} 3. ^1 {{Cite web|url=http://adisinsight.springer.com/drugs/800030372|title=Namilumab - AdisInsight|website=adisinsight.springer.com|language=en|access-date=2017-03-24}} 4. ^{{Cite web|url=https://clinicaltrials.gov/ct2/show/NCT02129777|title=Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis - Full Text View - ClinicalTrials.gov|website=clinicaltrials.gov|language=en|access-date=2017-03-24}} 5. ^{{Cite web|url=http://adisinsight.springer.com/trials/700252626|title=A 24-week Randomized, Open-Label, Parallel-Group, Active-Controlled, Exploratory, Proof-of-Mechanism Imaging Study Investigating the Efficacy of 150 mg of Namilumab Administered Subcutaneously vs Adalimumab in Patients With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate - AdisInsight|website=adisinsight.springer.com|language=en|access-date=2017-03-24}} 6. ^{{Cite web|url=https://clinicaltrials.gov/ct2/show/NCT02379091|title=Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA) - Full Text View - ClinicalTrials.gov|website=clinicaltrials.gov|language=en|access-date=2017-03-24}} 7. ^{{Cite web|url=https://www.takedaclinicaltrials.com/browse/summary/Namilumab-1003?protocol_id=#overview|title=Takeda clinical trials summary:Namilumab|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}} 1 : Monoclonal antibodies |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。